💛 A quick favor, if you've got a second.
We're really happy that you chose to read one of our stories and sincerely hope you'll stick around to read more. We took our paywall down — for now — but that won't last forever, and when the gate goes back up, we'd love for you to already be on the inside.
It's free. So please enter your email here and don't forget to like and follow us on all of your favorite Social Media platforms!
Federal regulators cleared a novel therapeutic agent on Wednesday intended to improve survival prospects for patients battling advanced pancreatic cancer that has spread beyond the primary tumor site. The Food and Drug Administration’s decision marks a significant development in the treatment landscape for this aggressive malignancy.
Metastatic pancreatic cancer remains one of the most challenging malignancies to treat, with historically limited therapeutic options available to oncologists and their patients. The agency’s approval represents a meaningful advancement in addressing an unmet medical need within this patient population.
More Stories
Four Kitchen Staples That Belong Outside the Freezer, According to Culinary Experts
New York Health Officials Sound Alarm Over Rising Measles Cases as School Year Approaches
CareCloud Breach Compromises 3.75 Million Patient Records, Among Largest Healthcare Data Thefts of 2026